Pioneering treatments for Duchenne muscular dystrophy
Research led by Professor Steve Wilton and Professor Sue Fletcher and licensed to Sarepta Therapeutics has delivered two treatments for Duchenne muscular dystrophy (DMD), with the drugs gaining accelerated approval by the U.S. Food and Drug Administration.
Areas of research
Molecular Medicine, Duchenne Muscular Dystrophy
Technology utilised
N/A
Lead researchers
Professor Steve Wilton, Professor Sue Fletcher